Recent advances in immunotherapy targeting CETP proteins for atherosclerosis prevention
Cholesteryl ester transfer protein (CETP) plays a key role in lipoprotein metabolism, and its activity has been linked to the risk of atherosclerosis (AS). CETP inhibitors, such as obicetrapib, represent a novel approach in immunotherapy to reduce the risk of atherosclerotic cardiovascular disease (...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2025.2462466 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832096637603807232 |
|---|---|
| author | Wenhui Hu Han Feng Ying Liu Xiaoshuang Xu Ping Zhou Zhonghua Sun Xinyu Tao Jiahui Yang Jun Wu Chen Qu Zhengxia Liu |
| author_facet | Wenhui Hu Han Feng Ying Liu Xiaoshuang Xu Ping Zhou Zhonghua Sun Xinyu Tao Jiahui Yang Jun Wu Chen Qu Zhengxia Liu |
| author_sort | Wenhui Hu |
| collection | DOAJ |
| description | Cholesteryl ester transfer protein (CETP) plays a key role in lipoprotein metabolism, and its activity has been linked to the risk of atherosclerosis (AS). CETP inhibitors, such as obicetrapib, represent a novel approach in immunotherapy to reduce the risk of atherosclerotic cardiovascular disease (ASCVD) by targeting lipid metabolism. In addition, CETP vaccines are being explored as a novel strategy for the prevention and treatment of ASCVD by inducing the body to produce antibodies against CETP, which is expected to reduce CETP activity, thereby increasing high-density lipoproteins (HDL) levels. This paper provides a comprehensive overview of the structure of CETP, the mechanisms of lipid transfer and the progress of immunotherapy in the last decade, which provides possible ideas for future development of novel drugs and optimization of immunization strategies. |
| format | Article |
| id | doaj-art-03e6eff067bb48e1b486de85b96ca02d |
| institution | Kabale University |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-03e6eff067bb48e1b486de85b96ca02d2025-02-05T12:27:44ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2025-12-0121110.1080/21645515.2025.2462466Recent advances in immunotherapy targeting CETP proteins for atherosclerosis preventionWenhui Hu0Han Feng1Ying Liu2Xiaoshuang Xu3Ping Zhou4Zhonghua Sun5Xinyu Tao6Jiahui Yang7Jun Wu8Chen Qu9Zhengxia Liu10Department of Geriatrics, The Second Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, P.R. ChinaDepartment of Geriatrics, The Second Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, P.R. ChinaDepartment of Geriatrics, The Second Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, P.R. ChinaKey Laboratory for Aging & Disease, Nanjing Medical University, Nanjing, Jiangsu, P.R. ChinaDepartment of Geriatrics, The Second Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, P.R. ChinaDepartment of Geriatrics, The Second Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, P.R. ChinaDepartment of Geriatrics, The Second Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, P.R. ChinaDepartment of Geriatrics, The Second Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, P.R. ChinaDepartment of Geriatric Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Geriatrics, The Second Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, P.R. ChinaDepartment of Geriatrics, The Second Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, P.R. ChinaCholesteryl ester transfer protein (CETP) plays a key role in lipoprotein metabolism, and its activity has been linked to the risk of atherosclerosis (AS). CETP inhibitors, such as obicetrapib, represent a novel approach in immunotherapy to reduce the risk of atherosclerotic cardiovascular disease (ASCVD) by targeting lipid metabolism. In addition, CETP vaccines are being explored as a novel strategy for the prevention and treatment of ASCVD by inducing the body to produce antibodies against CETP, which is expected to reduce CETP activity, thereby increasing high-density lipoproteins (HDL) levels. This paper provides a comprehensive overview of the structure of CETP, the mechanisms of lipid transfer and the progress of immunotherapy in the last decade, which provides possible ideas for future development of novel drugs and optimization of immunization strategies.https://www.tandfonline.com/doi/10.1080/21645515.2025.2462466CETPatherosclerosisimmunotherapyinhibitorvaccination |
| spellingShingle | Wenhui Hu Han Feng Ying Liu Xiaoshuang Xu Ping Zhou Zhonghua Sun Xinyu Tao Jiahui Yang Jun Wu Chen Qu Zhengxia Liu Recent advances in immunotherapy targeting CETP proteins for atherosclerosis prevention Human Vaccines & Immunotherapeutics CETP atherosclerosis immunotherapy inhibitor vaccination |
| title | Recent advances in immunotherapy targeting CETP proteins for atherosclerosis prevention |
| title_full | Recent advances in immunotherapy targeting CETP proteins for atherosclerosis prevention |
| title_fullStr | Recent advances in immunotherapy targeting CETP proteins for atherosclerosis prevention |
| title_full_unstemmed | Recent advances in immunotherapy targeting CETP proteins for atherosclerosis prevention |
| title_short | Recent advances in immunotherapy targeting CETP proteins for atherosclerosis prevention |
| title_sort | recent advances in immunotherapy targeting cetp proteins for atherosclerosis prevention |
| topic | CETP atherosclerosis immunotherapy inhibitor vaccination |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2025.2462466 |
| work_keys_str_mv | AT wenhuihu recentadvancesinimmunotherapytargetingcetpproteinsforatherosclerosisprevention AT hanfeng recentadvancesinimmunotherapytargetingcetpproteinsforatherosclerosisprevention AT yingliu recentadvancesinimmunotherapytargetingcetpproteinsforatherosclerosisprevention AT xiaoshuangxu recentadvancesinimmunotherapytargetingcetpproteinsforatherosclerosisprevention AT pingzhou recentadvancesinimmunotherapytargetingcetpproteinsforatherosclerosisprevention AT zhonghuasun recentadvancesinimmunotherapytargetingcetpproteinsforatherosclerosisprevention AT xinyutao recentadvancesinimmunotherapytargetingcetpproteinsforatherosclerosisprevention AT jiahuiyang recentadvancesinimmunotherapytargetingcetpproteinsforatherosclerosisprevention AT junwu recentadvancesinimmunotherapytargetingcetpproteinsforatherosclerosisprevention AT chenqu recentadvancesinimmunotherapytargetingcetpproteinsforatherosclerosisprevention AT zhengxialiu recentadvancesinimmunotherapytargetingcetpproteinsforatherosclerosisprevention |